{
  "docId": "019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "docSlug": "2cfade3d34acc49c8d5f05063b654956",
  "documentTitle": "ATAI | Investor Presentation Deck | 49 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 49,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a checkmark matrix to highlight the competitive advantage of the company's lead asset against standard-of-care classes like SSRIs, SNRIs, and Benzodiazepines.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-19a4-704e-b5bc-b8f4ae0c7550/27",
  "deckHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "deckJsonHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550.json",
  "deckAnchorHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "There is an unmet need in GAD for therapies with rapid onset, high efficacy, and minimal side effects. SSRI's are current standard of care for GAD but require 4-6 weeks for onset of effect and have several disadvantages.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "856f4e6f-d6fc-4dc7-b5d3-1a565f867c80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.7,
        "x": 0.26,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Note: GABA = Gamma aminobutyric acid, SERT = serotonin transporter, NET = serotonin transporter; MoA = Mechanism of Action; 5HT1a = serotonin 1A receptor; VDCC = voltage dependent calcium channel; TSPO = mitochondrial translocator protein. Source: GlobalData, Evaluate Pharma (both as of 19.03.2021) (1) DeMartini et al., “Generalized Anxiety Disorder” (2019)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "736cf1db-5ad2-45bd-91a5-61278502a2e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.7,
        "x": 0.26,
        "y": 0.22
      },
      "kind": "table",
      "text": "Comparison matrix of GAD therapeutic options across safety, onset, side effects, and addiction profiles.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d261494d-1e3a-47d1-9162-2cca6899c89d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.26,
        "y": 0.06
      },
      "kind": "title",
      "text": "GRX-917 can fill unmet need in Generalized Anxiety Disorder (GAD) with rapid onset and favorable safety profile",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b53eac15-1052-46db-bc75-409789e7abe6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "c01cc205-f933-4434-bfe1-778e810686ae",
      "evidence": "table/data: Comparison matrix of GAD therapeutic options across safety, onset, side effects, and addiction profiles.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "f1485794-34f2-4ab2-a92b-50803a33a62c",
      "evidence": "The slide uses a feature-comparison matrix to differentiate the product from competitors.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}